high titer convalescent COVID 19 plasma (HT-CCP) / Brigham and Womens Hospital - LARVOL DELTA

(ESCAPE): Evaluation of SARS-CoV-2 (COVID-19) Antibody-containing Plasma thErapy (clinicaltrials.gov) - P3; N=45; Terminated; Sponsor: Brigham and Women's Hospital; N=220 ➔ 45; Trial completion date: Dec 2021 ➔ Jun 2021; Recruiting ➔ Terminated; Futility

Clinical • Enrollment change • Trial completion date • Trial termination • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Some experts fear FDA’s plasma decision will hinder research; UMass doctor touts benefits (The Boston Globe) - "Some made 'very substantial, sometimes very dramatic improvements soon after receiving plasma,' said Gerber....Kaufman is leading a randomized controlled trial intended to assess the effectiveness of convalescent plasma, by giving half the patients plasma with antibodies against COVID-19, and half plasma from people who didn't have COVID-19. That trial will still go forward, despite the announcement Sunday. The Brigham is just starting to enroll patients, but the study will eventually involve other Boston hospitals and hospitals in Texas and Alabama, where COVID-19 infection rates are higher, Kaufman said....'I have concerns about the EUA making it harder to get definitive answers about whether this product works,' Kaufman said."

Media quote

Trials underway for COVID-19 plasma treatment - "Dr. Richard Kaufman...said the randomized trials are promising but cautions it's too early to tell if the treatment is viable. 'It's been harder than we thought it might be,' he said. 'This is true not just for our own trial, but others that are underway across the world. Nobody has been able to able to finish one yet.'"

Media quote

(ESCAPE): Evaluation of SARS-CoV-2 (COVID-19) Antibody-containing Plasma thErapy (clinicaltrials.gov) - P3; N=220; Recruiting; Sponsor: Brigham and Women's Hospital; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Infectious Disease • Novel Coronavirus Disease

(ESCAPE): Evaluation of SARS-CoV-2 Antibody-containing Plasma thErapy (clinicaltrials.gov) - P3; N=220; Not yet recruiting; Sponsor: Brigham and Women's Hospital

Clinical • New P3 trial • Infectious Disease • Novel Coronavirus Disease